Products
Publications
CNDO-201 (T. Suis Ova)
1. Bach JF. (2002). The effect of infections on susceptibility to autoimmune and allergic diseases. New Engl J Med, Vol. 347, No. 12: 912-920.
2. Becker, K. (2007). Autism, asthma, inflammation, and the hygiene hypothesis. Elsevier Medical Hypotheses. 69:731-740.
3. Cooke A. (2009). Review series on helminths, immune modulation and the hygiene hypothesis: how might infection modulate the onset of type 1 diabetes? Immunology. 2009 Jan;126(1):12-7.
4. Correale, J., Farez, M. (2007). Association Between Parasite Infection and Immune Responses in Multiple Sclerosis. American Neurological Association. DOI: 10.1002/ana.21067; 61:97-108.
5. Correale J, Farez MF. The impact of parasite infections on the course of multiple sclerosis. J Neuroimmunol. 2011 Apr;233(1-2):6-11. Epub 2011 Jan 31.
6. Elliott, D., Summers, R., Weinstock, J. (2007). Helminths as governors of immune-mediated inflammation. International Journal for Parasitology. 37:457-464
7. Fleming JO, Cook TD. Multiple sclerosis and the hygiene hypothesis. Neurology. 2006;67(11):2085-6.
8. Fleming, J., Isaak, A., Lee, J., Luzzio, C., Carrithers, M., Cook, T., Field, A., Boland, J. and Fabry, Z. (2011). Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study. Multiple Sclerosis Journal. DOI: 10.1177/1352458511398054
9. Reddy, A., Fried, B. (2007). The use of Trichuris suis and other helminth therapies to treat Crohn’s disease. Parasitol Res. 100:921-927.
10. Summers, R., Elliott, D., Qadir, K., Urban Jr., J., Thompson, R., Weinstock, J. (2003). Trichuris suis Seems to Be Safe and Possibly Effective in the Treatment of Inflammatory Bowel Disease. The American Journal of Gastroenterology. Vol. 98, No. 9.
11. Summers RW, Elliott DE, Urban JF, Thompson R, Weinstock JV. (2004). Trichuris suis therapy in Crohn’s disease. Gut. 2004; 13:11:18; ;000:1-4. Doi:10.1136/gut.2004.004179
12. Summers RW, Elliott DE, Urban JF, Thompson RA, Weinstock JV. (2005) Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology. 128:825-832.
13. Velasquez-Manoff, M. (June 29, 2008). The Worm Turns. The New York Times Magazine.
14. Weinstock JV, Elliott DE. Helminths and the IBD hygiene hypothesis. Inflamm Bowel Dis. 2009;15(1):128-33.
15. Wickelgren, I. (2004). Can Worms Tame the Immune System?. Science Magazine. VOL 305
16. Zozulya, A., Wiendel, H. (2008). The role of regulatory T cells in multiple sclerosis. Nature Clinical Practice, Neurology. Doi: 10.1038/ncpneuro 0832
CNDO-109 (Tumor Activated NK Cells)
1. Kottaridis, Tsirogianni M., P., North, J., Marden, C., Grace, S., Jide-Banwo, S., Sivakumaran, J., Lowdell, M.W. (2010.) Results of a phase 1 clinical trial of allogeneic tumor-primed natural killer cells in AML. American Society of Hematology 2011, Abstract 946.
2. Lowdell, M.W., Craston, R., Samuel, D., Wood, M.E., O'Neill, E., Saha, V. and Prentice, H.G. (2002). Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br. J. Haematol. 117:821-827.
3. Miller, J.S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S.A., Yun, G.H., Fautsch, S.K., McKenna, D., Le, C., Defor, T.E., Burns, L.J., Orchard, P.J., Blazar, B.R., Wagner, J.E., Slungaard, A., Weisdorf, D.J., Okazaki, I.J. and McGlave, P.B. (2005). Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051-3057.
4. North, J., Bakhsh, I., Marden, C., Pittman, H., Addison, E., Navarrete, C., Anderson, R. and Lowdell, M.W. (2007). Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation. J. Immunol. 178:85-94.
5. Rosenberg, S.A. (2005). The emergence of modern cancer immunotherapy. Ann. Surg. Oncol. 12:344-346.
6. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998;228:307–19.
7. Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W.D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M.F. and Velardi, A. (2002). Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097-2100.
1. Bach JF. (2002). The effect of infections on susceptibility to autoimmune and allergic diseases. New Engl J Med, Vol. 347, No. 12: 912-920.
2. Becker, K. (2007). Autism, asthma, inflammation, and the hygiene hypothesis. Elsevier Medical Hypotheses. 69:731-740.
3. Cooke A. (2009). Review series on helminths, immune modulation and the hygiene hypothesis: how might infection modulate the onset of type 1 diabetes? Immunology. 2009 Jan;126(1):12-7.
4. Correale, J., Farez, M. (2007). Association Between Parasite Infection and Immune Responses in Multiple Sclerosis. American Neurological Association. DOI: 10.1002/ana.21067; 61:97-108.
5. Correale J, Farez MF. The impact of parasite infections on the course of multiple sclerosis. J Neuroimmunol. 2011 Apr;233(1-2):6-11. Epub 2011 Jan 31.
6. Elliott, D., Summers, R., Weinstock, J. (2007). Helminths as governors of immune-mediated inflammation. International Journal for Parasitology. 37:457-464
7. Fleming JO, Cook TD. Multiple sclerosis and the hygiene hypothesis. Neurology. 2006;67(11):2085-6.
8. Fleming, J., Isaak, A., Lee, J., Luzzio, C., Carrithers, M., Cook, T., Field, A., Boland, J. and Fabry, Z. (2011). Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study. Multiple Sclerosis Journal. DOI: 10.1177/1352458511398054
9. Reddy, A., Fried, B. (2007). The use of Trichuris suis and other helminth therapies to treat Crohn’s disease. Parasitol Res. 100:921-927.
10. Summers, R., Elliott, D., Qadir, K., Urban Jr., J., Thompson, R., Weinstock, J. (2003). Trichuris suis Seems to Be Safe and Possibly Effective in the Treatment of Inflammatory Bowel Disease. The American Journal of Gastroenterology. Vol. 98, No. 9.
11. Summers RW, Elliott DE, Urban JF, Thompson R, Weinstock JV. (2004). Trichuris suis therapy in Crohn’s disease. Gut. 2004; 13:11:18; ;000:1-4. Doi:10.1136/gut.2004.004179
12. Summers RW, Elliott DE, Urban JF, Thompson RA, Weinstock JV. (2005) Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology. 128:825-832.
13. Velasquez-Manoff, M. (June 29, 2008). The Worm Turns. The New York Times Magazine.
14. Weinstock JV, Elliott DE. Helminths and the IBD hygiene hypothesis. Inflamm Bowel Dis. 2009;15(1):128-33.
15. Wickelgren, I. (2004). Can Worms Tame the Immune System?. Science Magazine. VOL 305
16. Zozulya, A., Wiendel, H. (2008). The role of regulatory T cells in multiple sclerosis. Nature Clinical Practice, Neurology. Doi: 10.1038/ncpneuro 0832
CNDO-109 (Tumor Activated NK Cells)
1. Kottaridis, Tsirogianni M., P., North, J., Marden, C., Grace, S., Jide-Banwo, S., Sivakumaran, J., Lowdell, M.W. (2010.) Results of a phase 1 clinical trial of allogeneic tumor-primed natural killer cells in AML. American Society of Hematology 2011, Abstract 946.
2. Lowdell, M.W., Craston, R., Samuel, D., Wood, M.E., O'Neill, E., Saha, V. and Prentice, H.G. (2002). Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br. J. Haematol. 117:821-827.
3. Miller, J.S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S.A., Yun, G.H., Fautsch, S.K., McKenna, D., Le, C., Defor, T.E., Burns, L.J., Orchard, P.J., Blazar, B.R., Wagner, J.E., Slungaard, A., Weisdorf, D.J., Okazaki, I.J. and McGlave, P.B. (2005). Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051-3057.
4. North, J., Bakhsh, I., Marden, C., Pittman, H., Addison, E., Navarrete, C., Anderson, R. and Lowdell, M.W. (2007). Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation. J. Immunol. 178:85-94.
5. Rosenberg, S.A. (2005). The emergence of modern cancer immunotherapy. Ann. Surg. Oncol. 12:344-346.
6. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998;228:307–19.
7. Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W.D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M.F. and Velardi, A. (2002). Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097-2100.